Abstract: The present invention provides a non-naturally occurring dendritic-like myeloid leukaemia cell according to ATCC Patent Deposit Designation PTA-123875, and methods and kits utilising such cells.
Type:
Grant
Filed:
September 24, 2018
Date of Patent:
November 14, 2023
Assignee:
SENZAGEN AB
Inventors:
Malin Marie Lindstedt, Carl A K Borrebaeck, Henrik Johansson, Robin Gradin
Abstract: The present invention relates to a method for identifying the skin sensitizer potency of a test agent, and arrays and analytical kits for use in such methods.
Type:
Grant
Filed:
March 22, 2017
Date of Patent:
May 10, 2022
Assignee:
SENZAGEN AB
Inventors:
Malin Marie Lindstedt, Carl A. K. Borrebaeck, Henrik Johansson, Ann-Sofie Albrekt, Kathrin Stephanie Zeller, Aakash Chawade, Tim Carl Sewe Lindberg, Andy Andreas Sebastian Forreryd
Abstract: The present invention relates to a method for identifying the skin sensitizer potency of a test agent, and arrays and analytical kits for use in such methods.
Type:
Application
Filed:
March 22, 2017
Publication date:
March 21, 2019
Applicant:
SENZAGEN AB
Inventors:
Malin Marie Lindstedt, Carl A.K. Borrebaeck, Henrik Johansson, Ann-Sofie Albrekt, Kathrin Stephanie Zeller, Aakash Chawade, Tim Carl Sewe Lindberg, Andy Andreas Sebastian Forreryd
Abstract: The present invention relates to an in vitro method for identifying agents capable of inducing sensitization of human skin and arrays and diagnostic kits for use in such methods. In particular, the methods include measurement of the expression of the biomarkers listed in Table 3A and/or 3B in MUTZ-3 cells exposed to a test agent.
Type:
Application
Filed:
October 26, 2011
Publication date:
October 17, 2013
Applicant:
SenzaGen AB
Inventors:
Malin Lindstedt, Carl Arne Krister Borrebaeck, Henrik Johansson, Ann-Sofie Albrekt
© 2024 Justia
